Dissecting bortezomib: development, application, adverse effects and future direction.
about
Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspectiveTrial Watch: Proteasomal inhibitors for anticancer therapyA virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivoFunctional chromatography reveals three natural products that target the same protein with distinct mechanisms of action.Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment.Multiple myeloma: practice patterns across Europe.Promising new strategies for hepatocellular carcinoma.Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma.The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.
P2860
Q26776294-CCEE2363-A2E8-43BC-8F82-44940E56996DQ28082910-BA9E527F-29D6-42D7-A22F-DCF630DF9353Q33977088-26100063-5ACF-453D-9250-DCAF27322759Q34295600-0EC0FDE4-7954-4C98-A94C-F6F30F506474Q35832168-08CC9122-08BA-41C7-8F0D-87220FB1CDC1Q37138590-2D9EE4C6-5E16-4B8E-8172-07618361FF67Q38862553-D16E0962-5495-48DF-953A-DEB620AA4C57Q38936589-67AE55E4-A4AF-4348-BE96-72AECE3AF5CCQ41932078-ECE2C4CE-1CB8-49E6-9A14-8D6400B1E85CQ48808585-4D2DC97E-1614-400C-A13D-D207F71E8439Q49358494-2F4935BD-7762-4CE3-BFE7-F650DEBB93B9Q52859066-62401941-DAA9-49DE-9031-0F4791231D54Q54112059-53E472B4-CA98-4533-A308-47A78BEBA38EQ54215275-C5A9210A-DD28-4428-8184-BC6E1BED7C7F
P2860
Dissecting bortezomib: development, application, adverse effects and future direction.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dissecting bortezomib: development, application, adverse effects and future direction.
@en
type
label
Dissecting bortezomib: development, application, adverse effects and future direction.
@en
prefLabel
Dissecting bortezomib: development, application, adverse effects and future direction.
@en
P2093
P1476
Dissecting bortezomib: development, application, adverse effects and future direction.
@en
P2093
P304
P356
10.2174/13816128113199990338
P577
2013-01-01T00:00:00Z